Summary
Elevated expression of interleukin-20 (IL-20) and its receptors has been demonstrated in synovium from patients with rheumatoid arthritis (RA) and is thought to be implicated in the pathogenesis of RA. NNC0109-0012 is a novel human monoclonal IgG4 antibody that binds to and neutralizes the activity of IL-20. Results of a Phase 2 study suggest that IL-20 is a potential target for RA therapy.
- Rheumatology Clinical Trials
- Rheumatoid Arthritis
- © 2012 MD Conference Express®